Literature DB >> 1713021

Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies.

M L Schmidt1, J Murray, V M Lee, W D Hill, A Wertkin, J Q Trojanowski.   

Abstract

A subset of demented elderly patients exhibit large numbers of cortical intraneuronal inclusions similar to the neurofilament (NF)-rich Lewy bodies (LB) found in pigmented subcortical neurons of patients with Parkinson's disease (PD). Because these cortical inclusions may contribute to the emergence of cognitive impairments in afflicted individuals, the authors mapped the distribution of NF epitopes in these so-called cortical LBs. This was done using ethanol-fixed tissues and a large library of monoclonal antibodies (MAbs) with well-characterized binding specificities to various regions of each NF triplet protein. Cortical LBs were examined by light, confocal, and electron microscopy, and they were compared with the subcortical LBs of PD and LBs in the peripheral nervous system (PNS). Monoclonal antibodies specific for the rod regions of each of the three NF subunits, or for phosphate-dependent and independent antigenic sites in the tail region of the high- (NF-H) and middle- (NF-M) molecular weight (Mr) NF subunits as well as other MAbs to the extreme COOH terminus of NF-L and NF-M or the head region of NF-M labeled a variable number of cortical LBs. Remarkably one of these anti-NF MAbs, RMO32, which recognized a phosphorylated epitope in the tail region of NF-M, immunolabeled nearly all cortical LBs, whereas each of the other anti-NF MAbs never labeled more than 10% of ubiquitin- or RMO32-positive cortical LBs. Further LBs in the PNS resembled those in the central nervous system (CNS) in their immunologic properties, and LBs in both sites were dominated by filamentous aggregates at the ultrastructural level. These findings suggest that NF proteins are profoundly altered during their incorporation into cortical and PNS LBs. Further the authors here identified immunologic and ultrastructural properties common to cortical LBs, PNS LBs, and classic substantia nigra LBs in PD. The accumulation of filamentous, perikaryal inclusions rich in NF proteins at diverse sites in the CNS and PNS of patients with a variety of neurodegenerative disorders suggests a widespread disruption of NF metabolism or transport.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713021      PMCID: PMC1886123     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Parkinson's disease and dementia with neuronal inclusions in the cerebral cortex: Lewy bodies or Pick bodies.

Authors:  J K Tiller-Borcich; L S Forno
Journal:  J Neuropathol Exp Neurol       Date:  1988-09       Impact factor: 3.685

2.  Cortical Lewy body dementia: clinical features and classification.

Authors:  W R Gibb; P J Luthert; I Janota; P L Lantos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

3.  Intraneuronal and extracellular neurofibrillary tangles exhibit mutually exclusive cytoskeletal antigens.

Authors:  M L Schmidt; R E Gur; R C Gur; J Q Trojanowski
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

4.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

Authors:  V M Lee; B J Balin; L Otvos; J Q Trojanowski
Journal:  Science       Date:  1991-02-08       Impact factor: 47.728

5.  Alzheimer disease tangles share immunological similarities with multiphosphorylation repeats in the two large neurofilament proteins.

Authors:  V M Lee; L Otvos; M L Schmidt; J Q Trojanowski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

6.  Properties of antigenic determinants that distinguish neurofibrillary tangles in progressive supranuclear palsy and Alzheimer's disease.

Authors:  M L Schmidt; V M Lee; H Hurtig; J Q Trojanowski
Journal:  Lab Invest       Date:  1988-10       Impact factor: 5.662

7.  Alz-50, ubiquitin and tau immunoreactivity of neurofibrillary tangles, Pick bodies and Lewy bodies.

Authors:  S Love; T Saitoh; S Quijada; G M Cole; R D Terry
Journal:  J Neuropathol Exp Neurol       Date:  1988-07       Impact factor: 3.685

8.  Ubiquitin and microtubule-associated protein tau immunoreactivity each define distinct structures with differing distributions and solubility properties in Alzheimer brain.

Authors:  G Shaw; V Chau
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

9.  Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques.

Authors:  D W Dickson; H Crystal; L A Mattiace; Y Kress; A Schwagerl; H Ksiezak-Reding; P Davies; S H Yen
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

10.  Epitopes that span the tau molecule are shared with paired helical filaments.

Authors:  K S Kosik; L D Orecchio; L Binder; J Q Trojanowski; V M Lee; G Lee
Journal:  Neuron       Date:  1988-11       Impact factor: 17.173

View more
  36 in total

1.  A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.

Authors:  I V Mersiyanova; A V Perepelov; A V Polyakov; V F Sitnikov; E L Dadali; R B Oparin; A N Petrin; O V Evgrafov
Journal:  Am J Hum Genet       Date:  2000-06-07       Impact factor: 11.025

2.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.

Authors:  J E Galvin; B Giasson; H I Hurtig; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases.

Authors:  Nigel J Cairns; Kunihiro Uryu; Eileen H Bigio; Ian R A Mackenzie; Marla Gearing; Charles Duyckaerts; Hideaki Yokoo; Yoichi Nakazato; Evelyn Jaros; Robert H Perry; Steven E Arnold; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2004-05-28       Impact factor: 17.088

Review 4.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

5.  Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies.

Authors:  Brittany N Dugger; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2010-08-19       Impact factor: 17.088

6.  Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.

Authors:  Deepak M Sampathu; Manuela Neumann; Linda K Kwong; Thomas T Chou; Matthew Micsenyi; Adam Truax; Jennifer Bruce; Murray Grossman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Am J Pathol       Date:  2006-10       Impact factor: 4.307

7.  Mallory body filaments become insoluble after normal assembly into intermediate filaments.

Authors:  M S Pollanen; P Markiewicz; L Weyer; M C Goh; C Bergeron
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

8.  Characterization of a shared epitope in cortical Lewy body fibrils and Alzheimer paired helical filaments.

Authors:  M S Pollanen; C Bergeron; L Weyer
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 9.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

10.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; M Hasegawa; M Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.